Results 191 to 200 of about 14,856,428 (286)

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring <i>BLM</i> mutation following CD19/CD22 bispecific CAR-T cell therapy. [PDF]

J Immunother Cancer
Liu X, Cong J, Xia X, Wang H, Yu X, Zheng Q, Wang L.   +6 more
europepmc   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study. [PDF]

Br J Haematol
Abeyakoon C, Wellard C, Murad V, Chung E, Hodgson D, Rodin D, Prica A, Aoki T, Vijenthira A, Falcone U, Opat S, Wood EM, McQuilten ZK, Hawkes EA, Crump M, Kuruvilla J, Gregory GP.   +16 more
europepmc   +1 more source

Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity

Rheumatology &Autoimmunity, EarlyView.
Jiekai Tan, Fanlei Hu, Chuanhui Xu
wiley   +1 more source

Neovascular glaucoma at a tertiary Centre in Finland, 2008–2024: A retrospective cohort study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes. Methods Patients with NVG were identified through electronic medical record review.
Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju   +3 more
wiley   +1 more source

Central nervous system lymphoma and neurolymphomatosis in equids. [PDF]

J Vet Intern Med
Aleman M, Calero MI, Woolard KD, O'Connell K, Berryhill E, Vernau W.   +5 more
europepmc   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Cow hooves and clover: Unusual morphology of peripheral T-cell lymphoma. [PDF]

Br J Haematol
Lu Y, Preston G, Laing G, Scott P.
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

From molecular pathogenesis to novel Therapeutic approaches - a review of recent advances in the treatment of peripheral T cell Lymphomas. [PDF]

Biomark Res
Chan WL, Chng WJ, Li QJ.
europepmc   +1 more source